Camurus AB (publ) (CAMRF)
USD 50.97
(0.0%)
USD 50.97
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 431.44 Million SEK | 676.63% |
| 2022 | 55.55 Million SEK | 161.42% |
| 2021 | -90.44 Million SEK | 45.93% |
| 2020 | -167.26 Million SEK | 42.3% |
| 2019 | -289.86 Million SEK | -23.52% |
| 2018 | -234.67 Million SEK | -23.14% |
| 2017 | -190.57 Million SEK | -135.3% |
| 2016 | -80.99 Million SEK | 49.23% |
| 2015 | -159.54 Million SEK | -430.0% |
| 2014 | 48.34 Million SEK | -51.28% |
| 2013 | 99.23 Million SEK | 645.18% |
| 2012 | 13.31 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 74.2 Million SEK | -4.71% |
| 2024 Q1 | 77.86 Million SEK | 612.06% |
| 2023 Q3 | 86.39 Million SEK | -71.34% |
| 2023 FY | 431.44 Million SEK | 676.63% |
| 2023 Q4 | -15.2 Million SEK | -117.6% |
| 2023 Q2 | 301.42 Million SEK | 412.37% |
| 2023 Q1 | 58.82 Million SEK | 350.21% |
| 2022 Q1 | -752 Thousand SEK | 94.63% |
| 2022 FY | 55.55 Million SEK | 161.42% |
| 2022 Q3 | 34.99 Million SEK | 324.8% |
| 2022 Q4 | 13.06 Million SEK | -62.66% |
| 2022 Q2 | 8.23 Million SEK | 1195.61% |
| 2021 Q3 | -6.16 Million SEK | 87.26% |
| 2021 Q4 | -14.01 Million SEK | -127.27% |
| 2021 FY | -90.44 Million SEK | 45.93% |
| 2021 Q1 | -21.87 Million SEK | 66.59% |
| 2021 Q2 | -48.38 Million SEK | -121.22% |
| 2020 Q1 | -61.55 Million SEK | 14.34% |
| 2020 FY | -167.26 Million SEK | 42.3% |
| 2020 Q4 | -65.47 Million SEK | -222.78% |
| 2020 Q3 | -20.28 Million SEK | -1.62% |
| 2020 Q2 | -19.96 Million SEK | 67.57% |
| 2019 Q4 | -71.85 Million SEK | -14.53% |
| 2019 Q1 | -67.62 Million SEK | 22.4% |
| 2019 Q2 | -87.64 Million SEK | -29.6% |
| 2019 Q3 | -62.73 Million SEK | 28.42% |
| 2019 FY | -289.86 Million SEK | -23.52% |
| 2018 Q2 | -67.5 Million SEK | -86.13% |
| 2018 FY | -234.67 Million SEK | -23.14% |
| 2018 Q4 | -87.14 Million SEK | -99.18% |
| 2018 Q3 | -43.75 Million SEK | 35.19% |
| 2018 Q1 | -36.26 Million SEK | 30.51% |
| 2017 FY | -190.57 Million SEK | -135.3% |
| 2017 Q3 | -52.33 Million SEK | -14.26% |
| 2017 Q4 | -52.19 Million SEK | 0.28% |
| 2017 Q1 | -40.24 Million SEK | -44.73% |
| 2017 Q2 | -45.8 Million SEK | -13.8% |
| 2016 Q1 | -19.41 Million SEK | 39.04% |
| 2016 FY | -80.99 Million SEK | 49.23% |
| 2016 Q3 | -13.21 Million SEK | 35.7% |
| 2016 Q4 | -27.8 Million SEK | -110.43% |
| 2016 Q2 | -20.55 Million SEK | -5.85% |
| 2015 Q2 | -115.17 Million SEK | -1227.24% |
| 2015 Q1 | 10.21 Million SEK | -86.35% |
| 2015 Q3 | -22.73 Million SEK | 80.26% |
| 2015 Q4 | -31.85 Million SEK | -40.07% |
| 2015 FY | -159.54 Million SEK | -430.0% |
| 2014 Q4 | 74.86 Million SEK | 4917.76% |
| 2014 Q3 | -1.55 Million SEK | 0.0% |
| 2014 FY | 48.34 Million SEK | -51.28% |
| 2013 FY | 99.23 Million SEK | 645.18% |
| 2012 FY | 13.31 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 675.54% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 6660.747% |
| SQZ Biotechnologies Company | -79.46 Million USD | 642.94% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -714.364% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -562.402% |
| Mesoblast Limited | -87.95 Million USD | 590.52% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 23798.729% |
| Genus plc | 7.9 Million USD | -5361.291% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 4061.185% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 11728.431% |
| Marizyme, Inc. | -65.34 Million USD | 760.233% |
| ContraFect Corporation | -65.15 Million USD | 762.198% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 4978.358% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 8930.054% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 25075.585% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 15016.433% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 5453.09% |
| MultiCell Technologies, Inc. | -380.07 USD | 113516557.495% |
| Accustem Sciences Inc. | -3.74 Million USD | 11616.117% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 934.64% |
| EV Biologics, Inc. | -1.26 Million USD | 34148.648% |
| Q BioMed Inc. | -2.05 Million USD | 21124.486% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 11657.514% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 68322.205% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 18221.191% |
| Biomind Labs Inc. | -1.21 Million USD | 35629.544% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 4190.273% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 5559.154% |
| Skye Bioscience, Inc. | -37.64 Million USD | 1246.087% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 19983.824% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 2880989.423% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 6278.607% |
| IMV Inc. | -36.48 Million USD | 1282.496% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 2818.354% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 7516.593% |
| GB Sciences, Inc. | -1.36 Million USD | 31784.607% |
| Alpha Cognition Inc. | -13.77 Million USD | 3232.619% |
| HST Global, Inc. | -146.21 Thousand USD | 295183.784% |
| CSL Limited | 2.64 Billion USD | 83.67% |
| Halberd Corporation | -79.67 Thousand USD | 541595.557% |
| Enzolytics Inc. | -2.17 Million USD | 19919.72% |
| Resverlogix Corp. | -3.61 Million USD | 12051.302% |
| Affymax, Inc. | -14.42 Million USD | 3091.14% |
| SYBLEU INC | -180.3 Thousand USD | 239385.873% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 13703.995% |
| argenx SE | -295.05 Million USD | 246.225% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 789.215% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -440146.939% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 10959.37% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 14357.196% |
| AVAX Technologies, Inc. | -6.41 Million USD | 6826.936% |
| Zenith Capital Corp. | -10.59 Million USD | 4171.744% |
| Genscript Biotech Corporation | -95.47 Million USD | 551.881% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 1856403.244% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 10506.384% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 713928.004% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 822.376% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 14009.551% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | 40954.045% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 22233.755% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 11397.251% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 21617.07% |
| BioStem Technologies, Inc. | -8.48 Million USD | 5185.97% |
| ONE Bio Corp. | 8.67 Million USD | -4872.471% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 97850.862% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 32407.323% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 24686.798% |
| Agentix Corp. | -1.37 Million USD | 31495.615% |
| LadRx Corporation | 400.44 Thousand USD | -107641.177% |
| Cell Source, Inc. | -5.32 Million USD | 8207.965% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 103942.071% |
| Regen BioPharma, Inc. | 1.02 Million USD | -42053.261% |
| Regen BioPharma, Inc. | 1.02 Million USD | -42053.261% |
| NovAccess Global Inc. | -4.76 Million USD | 9146.448% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -6130.575% |
| Itoco Inc. | -1.86 Million USD | 23184.171% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 9811.617% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 25950.33% |
| Kadimastem Ltd | -3.3 Million USD | 13144.756% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 157904.99% |
| CytoDyn Inc. | -49.84 Million USD | 965.637% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 546001.079% |
| Mobile Lads Corp. | -2.26 Million USD | 19162.587% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 189223.602% |
| Qrons Inc. | -789.34 Thousand USD | 54758.091% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 45923.549% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 20766.078% |
| Rebus Holdings, Inc. | -1.02 Million USD | 42398.235% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 26852.161% |
| International Stem Cell Corporation | -131 Thousand USD | 329445.038% |
| Bioxytran, Inc. | -4.28 Million USD | 10180.416% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 795062.412% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 17151.379% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 997.491% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 20508.798% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 55350.247% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 13718.75% |
| Neutra Corp. | -233.46 Thousand USD | 184899.435% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 2226.273% |
| PureTech Health plc | -65.69 Million USD | 756.715% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 2128.737% |
| IXICO plc | -1.17 Million USD | 36724.958% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 4446.147% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 855.22% |
| CSL Limited | 2.64 Billion USD | 83.67% |
| Cellectis S.A. | -103.17 Million USD | 518.17% |